Patents by Inventor Romesh Chandra Boruah

Romesh Chandra Boruah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Simultaneous method for the preparation of a mixture of 3-acetoxy-17-acetamido-16-formyl-androst-5,17-diene and 3-acetoxy-2'-chloro-5-androsteno[17,16-b]pyridine
    Patent number: 8513226
    Abstract: The present invention relates to preparation and biological evaluation of 3-acetoxy-17-acetamido-16-formyl-androst-5,17-diene (4) and 3-acetoxy2?-chloro-5-androsteno[17,16-b]pyridine (5) as gastric proton pump inhibitor and their comparison to that of omeprazole, a clinically employed anti-gastric ulcer drug. Compound (4) exhibited dose dependent inhibition of histamine-stimulated acid secretion in gastric parietal cell with an IC50 value comparable to cimetidine. No mortality or behavioral abnormality of Swiss albino mice was observed under single-dose level of 1 g/Kg body weight of compound (4). Compound (4) further exhibited excellent anti ulcer activity in vivo against indomethacin induced ulcer.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: August 20, 2013
    Assignee: Council of Scientific and Industrial Research
    Inventors: Romesh Chandra Boruah, Moyurima Borthakur, Madan Gopal Barthakur, Paruchuri Gangadhar Rao, Sudip Kumar Kar, Annalakshmi Chinniah, Suchandra Goswami, Pratap Kumar Das
  • Simultaneous Method for the Preparation of a Mixture of 3-acetoxy-17-acetamido-16-formyl-androst-5,17-diene and 3-acetoxy-2'-chloro-5-androsteno[17,16-b]pyridine
    Publication number: 20110028440
    Abstract: The present invention relates to preparation and biological evaluation of 3-acetoxy-17-acetamido-16-formyl-androst-5,17-diene (4) and 3-acetoxy2?-chloro-5-androsteno[17,16-b]pyridine (5) as gastric proton pump inhibitor and their comparison to that of omeprazole, a clinically employed anti-gastric ulcer drug. Compound (4) exhibited dose dependent inhibition of histamine-stimulated acid secretion in gastric parietal cell with an IC50 value comparable to cimetidine. No mortality or behavioral abnormality of Swiss albino mice was observed under single-dose level of 1 g/Kg body weight of compound (4). Compound (4) further exhibited excellent anti ulcer activity in vivo against indomethacin induced ulcer.
    Type: Application
    Filed: March 26, 2009
    Publication date: February 3, 2011
    Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Romesh Chandra Boruah, Moyurima Borthkur, Madan Gopal Barthakur, Paruchuri Gangadhar Rao, Sudip Kumar Kar, Annalaxmi Chinniah, Suchandra Goswami, Pratap Kumar Das